New breast cancer drug shows big survival boost
Enhertu, a drug from AstraZeneca and Daiichi Sankyo, is showing strong results for people with early-stage HER2-positive breast cancer.
In a major 2025 trial, Enhertu lowered the risk of the cancer coming back or causing death by 53% compared to the current go-to drug, Kadcyla.
Three years after treatment, 92% of patients on Enhertu were alive and free of invasive disease, versus 84% with Kadcyla.
The main downside? A higher chance of lung side effects (10% vs. 2%).
Enhertu could change the game for early-stage HER2-positive patients
Doctors are still figuring out if Enhertu works best before or after surgery, but they agree it's a big step forward for post-surgery care.
If these results hold up, Enhertu could become the new standard for treating early-stage HER2-positive breast cancer, opening up better options for thousands of patients.